According to CMS, the covered products are: Wegovy (semaglutide), all formulations, including the injection and the tablet Zepbound KwikPen (tirzepatide), the once-weekly injector pen only Foundayo (orforglipron), a once-daily pill, all formulations Important: Not every GLP-1 is covered under the Bridge
By 2008, the proposition that anti-manic drugs attenuated kinases for their therapeutic effect was put forth, including key kinases GSK3 (inhibited by lithium, valproate and ECT) and PKC (inhibited by chronic lithium, valproate and ECT) (Machado-Vieira et al., 2023)
These are usually felt for up to 2-3 days after the treatment
Sulforaphanes powerful antioxidant and anti-inflammatory mechanisms may explain why studies show its heart protective effects